
1. transfusion. 1994 jul;34(7):603-7.

confirmation hepatitis c infection: comparison five immunoblot assays.

zaaijer hl(1), vrielink h, van exel-oehlers pj, cuypers ht, lelie pn.

author information: 
(1)viral serology department, central laboratory netherlands red cross
blood transfusion service, amsterdam.

background: recently, new immunoblot assays detection antibodies to
hepatitis c virus (hcv) became available.
study design methods: performance five confirmatory anti-hcv
immunoblot assays studied samples known hcv antibody hcv rna
status. assays third-generation strip recombinant immunoblot assay
(riba-3, chiron corp., emeryville, ca), second-generation hcv blot (db-2 blot, 
diagnostic biotechnology, singapore), wellcozyme hcv western blot (murex
blot, murex diagnostics, dartford, uk), immunodot hcv assay (matrix, abbott
laboratories, chicago, il), third-generation hcv line immunoassay
(liatek-iii, organon teknika, boxtel, netherlands).
results: sensitivity samples 48 hcv rna-positive, second-generation riba 
(riba-2)-positive persons specificity samples 31 low-risk donors 
96 percent better assays. sensitivity 31 hcv rna-positive,
riba-2-indeterminate samples follows: liatek-iii, 94 percent; riba-3, 90
percent; murex blot, 61 percent; matrix, 55 percent; db-2 blot, 39 percent.
in testing 39 hcv rna-negative, riba-2-indeterminate donor samples, the
percentage found negative liatek-iii, 77 percent; riba-3, 67 percent;
murex blot, 49 percent; db-2 blot, 33 percent; matrix, 15 percent. order 
of sensitivity four hcv seroconversion series (from high low): riba-3, 
liatek-iii, db-2 blot, murex blot, matrix; differences small.
conclusion: detection hcv antibodies refined addition new
hcv antigens (ns5, e2/ns1), improved classical antigens (core, ns3, ns4). 
replacement commonly used riba-2 resolve status high
proportion riba-2-indeterminate samples.

doi: 10.1046/j.1537-2995.1994.34794330015.x 
pmid: 7519796  [indexed medline]

